Friday, 16 June 2017

Cinnamaldehyde kháng K562

Erythroid Precursor Cells: Advances in Research and Application: ...

https://books.google.com.vn/books?id=vxkthkXb5osC&pg=PP7&lpg=PP7&dq=K562+cells&source=bl&ots=j8FRTDGS76&sig=dEKWKpPRV3fZ5TlhIituQcl2--Y&hl=en&sa=X&ved=0ahUKEwiDy9OtlcHUAhUBE5QKHQpiB-w4HhDoAQhQMAY#v=onepage&q=K562%20cells&f=false

Cinnamaldehyde kháng K562

From Wikipedia, the free encyclopedia
Cinnamaldehyde
Skeletal formula of cinnamaldehyde
Ball-and-stick model of the cinnamaldehyde molecule
Names
Preferred IUPAC name
(2E)-3-Phenylprop-2-enal
Other names
Cihinnamaldehyde
Cinnamic aldehyde
trans-Cinnamaldehyde
Identifiers
3D model (JSmol)
ChEBI
ChemSpider
ECHA InfoCard100.002.922
EC Number203-213-9
KEGG
PubChem CID
RTECS numberGD6475000
UNII
Properties
C9H8O
Molar mass132.16 g/mol
AppearanceYellow oil
Odorpungent, cinnamon-like
Density1.0497 g/mL
Melting point−7.5 °C (18.5 °F; 265.6 K)
Boiling point248 °C (478 °F; 521 K)
Slightly Soluble
Solubilitysoluble in etherchloroform
insoluble in petroleum ether
miscible with alcoholoils
-74.8·10−6 cm3/mol
1.6195
Hazards
R-phrases(outdated)R36 R37 R38
S-phrases(outdated)S26 S36
NFPA 704
Flammability code 2: Must be moderately heated or exposed to relatively high ambient temperature before ignition can occur. Flash point between 38 and 93 °C (100 and 200 °F). E.g., diesel fuelHealth code 2: Intense or continued but not chronic exposure could cause temporary incapacitation or possible residual injury. E.g., chloroformReactivity code 0: Normally stable, even under fire exposure conditions, and is not reactive with water. E.g., liquid nitrogenSpecial hazards (white): no codeNFPA 704 four-colored diamond
2
2
0
Flash point71 °C (160 °F; 344 K)
Lethal dose or concentration (LDLC):
LD50 (median dose)
3400 mg/kg (rat, oral)
Related compounds
Related compounds
Cinnamic acid
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 verify (what is Yes ?)
Infobox references
Cinnamaldehyde is an organic compound with the formula C6H5CH=CHCHO. Occurring naturally as predominately the trans (E) isomer, it gives cinnamon its flavor and odor.[1] It is a flavonoid that is naturally synthesized by the shikimate pathway.[2] This pale yellow, viscous liquid occurs in the bark of cinnamon trees and other species of the genusCinnamomum. The essential oil of cinnamon bark is about 50% cinnamaldehyde.[3]

Structure and synthesis[edit]

Cinnamaldehyde was isolated from cinnamon essential oil in 1834 by Dumas and Péligot[4] and synthesized in the laboratory by the Italian chemist Luigi Chiozza (1828-1889) in 1854.[5]
The natural product is trans-cinnamaldehyde. The molecule consists of a benzene ring attached to an unsaturated aldehyde. As such, the molecule can be viewed as a derivative of acrolein. Its color is due to the π → π* transition: increased conjugation in comparison with acrolein shifts this band towards the visible.[6]

Biosynthesis[edit]


Pathway for the biosynthesis of cis-cinnamaldehyde.
The biosynthesis of cinnamaldehyde begins with deamination of L-phenylalalanine into cinnamic acid by the action of phenylalanine ammonia lyase (PAL).[7][8] PAL catalyzes this reaction by a non-oxidative deamination. This deamination relies on the MIO prosthetic group of PAL.[9] PAL gives rise to trans-cinnamic acid.
In the second step, 4-coumarate: CoA ligase (4CL) converts cinnamic acid to cinnamoyl-CoA by an acid-thiol ligation.[7]4CL uses ATP to catalyze the formation of cinnamoyl-CoA.[10] 4CL effects this reaction in two steps.[11] 4CL forms a hydroxycinnamate-AMP anhydride, followed by a nucleophile attack on the carbonyl of the acyl adenylate.[12]
Cinnamoyl-CoA is reduced by NADPH catalyzed by CCR (cinnamoyl-CoA reductase) to form cinnamaldehyde.[7][13]

Synthesis[edit]

Several methods of laboratory synthesis exist, but cinnamaldehyde is most economically obtained from the steam distillation of the oil of cinnamon bark. The compound can be prepared from related compounds such as cinnamyl alcohol, (the alcohol form of cinnamaldehyde), but the first synthesis from unrelated compounds was the aldol condensation of benzaldehyde and acetaldehyde.

Metabolism[edit]

Cinnamaldehyde occurs widely, and closely related compounds give rise to lignin. All such compounds are biosynthesized starting from phenylalanine, which undergoes conversion.[14]
Cinnamoyl-CoA reductase is an enzyme responsible for the production of cinnamoyl-CoA from cinnamaldehyde.

Applications[edit]

As a flavorant[edit]

The most obvious application for cinnamaldehyde is as flavoring in chewing gumice creamcandy, and beverages; use levels range from 9 to 4900 parts per million (ppm) (that is, less than 0.5%). It is also used in some perfumes of natural, sweet, or fruity scentsAlmondapricotbutterscotch, and other aromas may partially employ the compound for their pleasant smells. Cinnamaldehyde can be used as a food adulterant; powdered beechnut husk aromatized with cinnamaldehyde can be marketed as powdered cinnamon.[15] Some breakfast cereals contain as much as 187 ppm cinnamaldehyde.[16]

As an agrichemical[edit]

Cinnamaldehyde is also used as a fungicide.[17] Proven effective on over 40 different crops, cinnamaldehyde is typically applied to the root systems of plants. Its low toxicity and well-known properties make it ideal for agriculture. Cinnamaldehyde is an effective insecticide, and its scent is also known to repel animals, such as cats and dogs.[17] It has been tested as a safe and effective insecticide against mosquito larvae.[18] A concentration of 29 ppm of cinnamaldehyde kills half of Aedes aegypti mosquito larvae in 24 hours.[19] Trans-cinnamaldehyde works as a potent fumigant and practical repellant for adult mosquitos.[20]

Miscellaneous uses[edit]

Cinnamaldehyde is also known as a corrosion inhibitor for steel and other ferrous alloys in corrosive fluids such as hydrochloric acid. It is believed that this is achieved by polymerization to form a protective film on the metal surface.[21][22] It can be used in combination with additional components such as dispersing agents, solventsand other surfactants. Cinnamaldehyde is also a potent inducer of apoptosis via ROS-mediated mitochondrial permeability transition in human promyelocytic leukemia HL-60 cells.[23] Cinnamaldehyde also has antimicrobial properties.[24] Cinnamaldehyde is also a TRPA1 activator, and can excite a subset of sensory neurons that are mainly cold-sensitive neurons, to cause nociceptive behavior in mice.[25]

Derivatives[edit]

Numerous derivatives of cinnamaldehyde are commercially useful. Dihydrocinnamyl alcohol, which occurs naturally but is produced by double hydrogenation of cinnamaldehyde, is used to confer the fragrances of hyacinth and lilac. Cinnamyl alcohol similarly occurs naturally and has the odor of lilac, but can be also produced starting from cinnamaldehyde.[26] Dihydrocinnamaldehyde is produced by the selective hydrogenation of the alkene subunit. α-Amyl- and α-hexylcinnamaldehyde are important commercial fragrances, but they are not prepared from cinnamaldehyde.[15]

Toxicology[edit]

Cinnamaldehyde is used in agriculture because of its low toxicity, but it is a skin irritant.[27]

Lapatinib kháng K562

Lapatinib Induces Autophagy, Apoptosis and Megakaryocytic ... - PLOS

Lapatinib kháng K562

From Wikipedia, the free encyclopedia
Lapatinib
Lapatinib.svg
Clinical data
Trade namesTykerb, Tyverb
AHFS/Drugs.comMonograph
MedlinePlusa607055
License data
Pregnancy
category
  • AU: D
  • US: D (Evidence of risk)
    Routes of
    administration
    By mouth (tablets)
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)
    • CA℞-only
    • UK: POM (Prescription only)
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Pharmacokinetic data
    BioavailabilityVariable, increased with food
    Protein binding>99%
    MetabolismHepatic, mostly CYP3A-mediated (minor 2C19 and 2C8involvement)
    Biological half-life24 hours (repeated dosing), 14.2 hours (single dose)
    ExcretionMostly fecal
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    ECHA InfoCard100.170.767
    Chemical and physical data
    FormulaC29H26ClFN4O4S
    Molar mass581.058 g/mol
    3D model (Jmol)
     Yes (what is this?)  (verify)
    Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb) is an orally active drug for breast cancer and other solid tumours.[1] It is a dual tyrosine kinase inhibitor which interrupts the HER2/neuand epidermal growth factor receptor (EGFR) pathways.[2] It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).[3]

    Status[edit]

    On March 13, 2007, the U.S. Food and Drug Administration (FDA) approved lapatinib in combination therapy for breast cancer patients already using capecitabine (Xeloda).[2][3] In January 2010, Tykerb received accelerated approval for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor and for whom hormonal therapy is indicated (in combination with letrozole).[3]
    Pharmaceutical company GlaxoSmithKline (GSK) markets the drug under the propriety names Tykerb (mostly U.S.) and Tyverb (mostly Europe and Russia).[4] The drug currently has approval for sale and clinical use in the US,[2][4]Australia,[2] Bahrain,[2] Kuwait,[2] Venezuela,[2] Brazil,[5] New Zealand,[5] South Korea,[5] Switzerland,[4] Japan, Jordan, the European Union, Lebanon, India and Pakistan.[4]
    On the August 2, 2013, India's Intellectual Property Appellate Board revoked the patent for Glaxo's Tykerb citing its derivative status, while upholding at the same time the original patent granted for lapatinib.[6]
    The drug lapatinib ditosylate is classified as S/NM (a synthetic compound showing competitive inhibition of the natural product) that is naturally derived or inspired substrate (Gordon M. Cragg, Paul G. Grothaus, and David J. Newman, Impact of Natural Products on Developing New Anti-Cancer Agents, Chem. Rev. 2009, 109, 3012–3043)

    Mode of action[edit]

    Biochemistry[edit]

    Lapatinib inhibits the tyrosine kinase activity associated with two oncogenesEGFR (epidermal growth factor receptor) and HER2/neu (human EGFR type 2).[7] Over expression of HER2/neu can be responsible for certain types of high-risk breast cancers in women.[2]
    Like sorafenib, lapatinib is a protein kinase inhibitor shown to decrease tumor-causing breast cancer stem cells.[8]
    Lapatinib inhibits receptor signal processes by binding to the ATP-binding pocket of the EGFR/HER2 protein kinasedomain, preventing self-phosphorylation and subsequent activation of the signal mechanism (see Receptor tyrosine kinase#Signal transduction).[9]

    Clinical application[edit]

    Breast cancer[edit]

    Lapatinib is used as a treatment for women's breast cancer in treatment-naïve, ER+/EGFR+/HER2+ breast cancer patients and in patients who have HER2-positive advanced breast cancer that has progressed after previous treatment with other chemotherapeutic agents, such as anthracyclinetaxane-derived drugs, or trastuzumab (Herceptin).
    A 2006 GSK-supported randomized clinical trial on female breast cancer previously being treated with those agents (anthracycline, a taxane and trastuzumab) demonstrated that administrating lapatinib in combination with capecitabinedelayed the time of further cancer growth compared to regimens that use capecitabine alone. The study also reported that risk of disease progression was reduced by 51%, and that the combination therapy was not associated with increases in toxic side effects.[10] The outcome of this study resulted in a somewhat complex and rather specific initial indication for lapatinib—use only in combination with capecitabine for HER2-positive breast cancer in women whose cancer have progressed following previous chemotherapy with anthracycline, taxanes and trastuzumab.

    Adverse effects[edit]

    Like many small molecule tyrosine kinase inhibitors, lapatinib is regarded as well tolerated. The most common side effects reported are diarrheafatiguenausea and rashes.[2][11] In clinical studies elevated liver enzymes have been reported. QT prolongation has been observed with the use of lapatinib ditosylate but there are no reports of torsades de pointes. Caution is advised in patients with hypokalaemia, hypomagnesaemia, congenital long QT syndrome, or with coadministration of medicines known to cause QT prolongation. In combination with capecitabine, reversible decreased left ventricular function are common (2%).[12]

    Ongoing trials in gastric cancer[edit]

    Phase III study designed to assess lapatinib in combination with chemotherapy for advanced HER2-positive gastric cancer in 2013 failed to meet the primary endpoint of improved overall survival (OS) against chemotherapy alone. The trial did not discover new safety signals, while the median OS for patients in the lapatinib and chemotherapy group was 12.2 months against 10.5 months for patients in the placebo plus chemotherapy. Secondary endpoints of the randomized, double-blinded study, were progression-free survival (PFS), response rate and duration of response. Median PFS was 6 months, response rate was 53% and the duration of response was 7.3 months in the investigational combination chemotherapy group compared to median PFS of 5.4 months, response rate of 39% and duration of response of 5.6 months for patients in chemotherapy alone group. Diarrhoea, vomiting, anemia, dehydration and nausea were serious adverse events (SAE) reported in over 2% of patients in the investigational combination chemotherapy group, while vomiting was the most common SAE noted in the chemotherapy group.[13]